Top Markets
Coin of the day
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Classement en actions #15974
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Prix de l'action
$15.42
Capitalisation boursière
$320.83M
Changement (1 jour)
-1.52%
Changement (1 an)
40.67%
Pays
IT
Échange Newron Pharmaceuticals S.p.A. (NP5)

Catégorie

Ratio P/B pour Newron Pharmaceuticals S.p.A. (NP5)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Newron Pharmaceuticals S.p.A., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Newron Pharmaceuticals S.p.A. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH